Hexokinase

metformin thead th colspan=”2″ align=”still left” valign=”middle” rowspan=”1″ /th th align=”middle” valign=”middle” rowspan=”1″ colspan=”1″ Metformin br / N=489,979 /th th colspan=”3″ align=”middle” valign=”middle” rowspan=”1″ glimepiride br / N=50,022 /th th colspan=”3″ align=”middle” valign=”middle” rowspan=”1″ glipizide br / N=149,949 /th th colspan=”3″ align=”middle” valign=”middle” rowspan=”1″ glyburide br / N=109,681 /th /thead Person-years of follow-up122,69412,51036,27926,277Outcomes within 180 times of cohort admittance1,5577141,7891,834Average daily dosage (milligrams/time)Median (Q1CQ3)1,000 (1,000C2,000)4

metformin thead th colspan=”2″ align=”still left” valign=”middle” rowspan=”1″ /th th align=”middle” valign=”middle” rowspan=”1″ colspan=”1″ Metformin br / N=489,979 /th th colspan=”3″ align=”middle” valign=”middle” rowspan=”1″ glimepiride br...